Medirom Healthcare Technologies Net Income
| MRM Stock | USD 1.32 0.00 0.00% |
As of the 16th of February 2026, Medirom Healthcare secures the Risk Adjusted Performance of (0.16), standard deviation of 2.93, and Mean Deviation of 2.14. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Medirom Healthcare, as well as the relationship between them. Please verify Medirom Healthcare mean deviation, treynor ratio, as well as the relationship between the Treynor Ratio and kurtosis to decide if Medirom Healthcare Technologies is priced some-what accurately, providing market reflects its recent price of 1.32 per share. Given that Medirom Healthcare is a hitting penny stock territory we strongly suggest to closely look at its jensen alpha.
Medirom Healthcare Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 0.6805 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 158.9 M | 166.9 M | |
| Net Loss | -891.7 M | -847.1 M | |
| Net Income | 158.9 M | 166.9 M | |
| Net Income Per Share | 26.21 | 27.52 | |
| Net Income Per E B T | 2.81 | 1.60 |
Medirom | Net Income | Build AI portfolio with Medirom Stock |
Evaluating Medirom Healthcare's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Medirom Healthcare Technologies's fundamental strength.
Latest Medirom Healthcare's Net Income Growth Pattern
Below is the plot of the Net Income of Medirom Healthcare Technologies over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Medirom Healthcare financial statement analysis. It represents the amount of money remaining after all of Medirom Healthcare Technologies operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Medirom Healthcare's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Medirom Healthcare's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 138.19 M | 10 Years Trend |
|
Net Income |
| Timeline |
Medirom Net Income Regression Statistics
| Arithmetic Mean | (8,958,249) | |
| Geometric Mean | 103,512,162 | |
| Coefficient Of Variation | (3,337) | |
| Mean Deviation | 177,880,530 | |
| Median | 66,310,000 | |
| Standard Deviation | 298,941,233 | |
| Sample Variance | 89365.9T | |
| Range | 1.2B | |
| R-Value | (0.07) | |
| Mean Square Error | 94839T | |
| R-Squared | 0.01 | |
| Significance | 0.79 | |
| Slope | (4,220,790) | |
| Total Sum of Squares | 1429853.8T |
Medirom Net Income History
Other Fundumenentals of Medirom Healthcare
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Medirom Healthcare Net Income component correlations
Medirom Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Medirom Healthcare is extremely important. It helps to project a fair market value of Medirom Stock properly, considering its historical fundamentals such as Net Income. Since Medirom Healthcare's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Medirom Healthcare's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Medirom Healthcare's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Health Care Providers & Services sector continue expanding? Could Medirom diversify its offerings? Factors like these will boost the valuation of Medirom Healthcare. Expected growth trajectory for Medirom significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Medirom Healthcare data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.278 | Earnings Share 0.39 | Revenue Per Share | Quarterly Revenue Growth (0.07) | Return On Assets |
Understanding Medirom Healthcare requires distinguishing between market price and book value, where the latter reflects Medirom's accounting equity. The concept of intrinsic value - what Medirom Healthcare's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Medirom Healthcare's price substantially above or below its fundamental value.
Understanding that Medirom Healthcare's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Medirom Healthcare represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Medirom Healthcare's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Medirom Healthcare 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Medirom Healthcare's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Medirom Healthcare.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Medirom Healthcare on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Medirom Healthcare Technologies or generate 0.0% return on investment in Medirom Healthcare over 90 days. Medirom Healthcare is related to or competes with YY Group, DSS, Bt Brands, Aterian, LOBO EV, Fly E, and FGI Industries. MEDIROM Healthcare Technologies Inc. provides holistic healthcare services in Japan More
Medirom Healthcare Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Medirom Healthcare's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Medirom Healthcare Technologies upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.23) | |||
| Maximum Drawdown | 16.0 | |||
| Value At Risk | (5.71) | |||
| Potential Upside | 3.76 |
Medirom Healthcare Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medirom Healthcare's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Medirom Healthcare's standard deviation. In reality, there are many statistical measures that can use Medirom Healthcare historical prices to predict the future Medirom Healthcare's volatility.| Risk Adjusted Performance | (0.16) | |||
| Jensen Alpha | (0.63) | |||
| Total Risk Alpha | (0.82) | |||
| Treynor Ratio | (1.26) |
Medirom Healthcare February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.16) | |||
| Market Risk Adjusted Performance | (1.25) | |||
| Mean Deviation | 2.14 | |||
| Coefficient Of Variation | (491.54) | |||
| Standard Deviation | 2.93 | |||
| Variance | 8.58 | |||
| Information Ratio | (0.23) | |||
| Jensen Alpha | (0.63) | |||
| Total Risk Alpha | (0.82) | |||
| Treynor Ratio | (1.26) | |||
| Maximum Drawdown | 16.0 | |||
| Value At Risk | (5.71) | |||
| Potential Upside | 3.76 | |||
| Skewness | (0.24) | |||
| Kurtosis | 1.27 |
Medirom Healthcare Backtested Returns
Medirom Healthcare has Sharpe Ratio of -0.26, which conveys that the firm had a -0.26 % return per unit of risk over the last 3 months. Medirom Healthcare exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Medirom Healthcare's Risk Adjusted Performance of (0.16), mean deviation of 2.14, and Standard Deviation of 2.93 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 0.48, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Medirom Healthcare's returns are expected to increase less than the market. However, during the bear market, the loss of holding Medirom Healthcare is expected to be smaller as well. At this point, Medirom Healthcare has a negative expected return of -0.72%. Please make sure to verify Medirom Healthcare's jensen alpha, as well as the relationship between the kurtosis and market facilitation index , to decide if Medirom Healthcare performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.17 |
Insignificant reverse predictability
Medirom Healthcare Technologies has insignificant reverse predictability. Overlapping area represents the amount of predictability between Medirom Healthcare time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Medirom Healthcare price movement. The serial correlation of -0.17 indicates that over 17.0% of current Medirom Healthcare price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.17 | |
| Spearman Rank Test | -0.32 | |
| Residual Average | 0.0 | |
| Price Variance | 0.05 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Medirom Healthcare Technologies reported net income of 138.19 M. This is 72.94% lower than that of the Health Care Providers & Services sector and 43.9% lower than that of the Health Care industry. The net income for all United States stocks is 75.8% higher than that of the company.
Medirom Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medirom Healthcare's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medirom Healthcare could also be used in its relative valuation, which is a method of valuing Medirom Healthcare by comparing valuation metrics of similar companies.Medirom Healthcare is currently under evaluation in net income category among its peers.
Medirom Healthcare Current Valuation Drivers
We derive many important indicators used in calculating different scores of Medirom Healthcare from analyzing Medirom Healthcare's financial statements. These drivers represent accounts that assess Medirom Healthcare's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Medirom Healthcare's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 3.4B | 3.2B | 4.2B | 827.6M | 951.7M | 904.1M | |
| Enterprise Value | 5.8B | 5.9B | 7.7B | 4.5B | 5.1B | 7.9B |
Medirom Healthcare Institutional Holders
Institutional Holdings refers to the ownership stake in Medirom Healthcare that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Medirom Healthcare's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Medirom Healthcare's value.| Shares | Ubs Group Ag | 2025-06-30 | 33.3 K | Citadel Advisors Llc | 2025-06-30 | 19.2 K | Mariner Wealth Advisors Llc | 2025-06-30 | 19 K | Rhumbline Advisers | 2025-06-30 | 1.1 K | Gamma Investing Llc | 2025-06-30 | 104 | Tower Research Capital Llc | 2025-06-30 | 11.0 | Warberg Asset Management Llc | 2025-03-31 | 0.0 | Heights Capital Management Inc | 2025-03-31 | 0.0 | Xtx Topco Ltd | 2025-06-30 | 0.0 |
Medirom Fundamentals
| Return On Equity | 0.53 | ||||
| Return On Asset | -0.0178 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 35.81 M | ||||
| Shares Outstanding | 7.9 M | ||||
| Shares Owned By Insiders | 26.41 % | ||||
| Shares Owned By Institutions | 0.28 % | ||||
| Number Of Shares Shorted | 136.42 K | ||||
| Price To Book | 6.64 X | ||||
| Price To Sales | 0 X | ||||
| Revenue | 8.3 B | ||||
| Gross Profit | 2.02 B | ||||
| EBITDA | 387.5 M | ||||
| Net Income | 138.19 M | ||||
| Cash And Equivalents | 354.95 M | ||||
| Cash Per Share | 72.70 X | ||||
| Total Debt | 3.96 B | ||||
| Current Ratio | 0.36 X | ||||
| Book Value Per Share | 0.20 X | ||||
| Cash Flow From Operations | (1.33 B) | ||||
| Short Ratio | 0.75 X | ||||
| Earnings Per Share | 0.39 X | ||||
| Target Price | 5.12 | ||||
| Number Of Employees | 334 | ||||
| Beta | 0.97 | ||||
| Market Capitalization | 10.51 M | ||||
| Total Asset | 8.09 B | ||||
| Retained Earnings | 229.04 M | ||||
| Working Capital | (1.48 B) | ||||
| Net Asset | 8.09 B |
About Medirom Healthcare Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medirom Healthcare Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medirom Healthcare using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medirom Healthcare Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Will Health Care Providers & Services sector continue expanding? Could Medirom diversify its offerings? Factors like these will boost the valuation of Medirom Healthcare. Expected growth trajectory for Medirom significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Medirom Healthcare data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.278 | Earnings Share 0.39 | Revenue Per Share | Quarterly Revenue Growth (0.07) | Return On Assets |
Understanding Medirom Healthcare requires distinguishing between market price and book value, where the latter reflects Medirom's accounting equity. The concept of intrinsic value - what Medirom Healthcare's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Medirom Healthcare's price substantially above or below its fundamental value.
Understanding that Medirom Healthcare's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Medirom Healthcare represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Medirom Healthcare's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.